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The induction of tumor cell death is one of themajor goals of radiotherapy and has been con-
sidered to be the central determinant of its therapeutic outcome for a long time. However,
accumulating evidence suggests that the success of radiotherapy does not only derive
from direct cytotoxic effects on the tumor cells alone, but instead might also depend – at
least in part – on innate aswell as adaptive immune responses, which can particularly target
tumor cells that survive local irradiation. The clearance of dying tumor cells by phagocytic
cells of the innate immune system represents a crucial step in this scenario. Dendritic cells
and macrophages, which engulf, process and present dying tumor cell material to adaptive
immune cells, can trigger, skew, or inhibit adaptive immune responses, respectively. In
this review we summarize the current knowledge of different forms of cell death induced
by ionizing radiation, the multi-step process of dying cell clearance, and its immunological
consequences with special regard toward the potential exploitation of these mechanisms
for the improvement of tumor radiotherapy.
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Radiotherapy is an essential treatment option for various types of
cancer due to its profound potential to kill malignant cells and to
abrogate clonogenic survival. Ionizing radiation, including X-rays,
gamma rays, and heavy ions, induces damages in the cellular DNA,
which lead to the activation of a highly sophisticated and ﬁnely
tuned signaling cascade designated the DNA damage response
(DDR) and – depending on the extent of damage – to transient or
permanent cell cycle arrest, and/or cell death, respectively.
THE DNA DAMAGE RESPONSE
The DDR is orchestrated by two conserved protein kinases, ATM
(ataxia telangiectasia, mutated) andATR (ATM and Rad3 related),
which in concert control the cellular response to DNA dou-
ble strand breaks (DSBs) and single-stranded (ss) DNA (Smith
et al., 2010). ATM is recruited to DSBs by the Mre11–Rad50–
Nbs1 (MRN) complex and phosphorylates the histone H2 variant
H2AX, thus generating an interaction platform for other DDR
constituents required for DSB repair (Shiloh, 2006). Concomi-
tantly, ATM activates the DNA damage checkpoint by initiating
the resection of the broken strand(s) leading to the generation
of ssDNA, a DNA damage repair intermediate which, in turn,
activates ATR kinase (Hurley and Bunz, 2007). ATR and ATM
phosphorylate and activate two respective effector kinases termed
Chk1 and Chk2. Collectively, these four protein kinases instigate
multiple cellular pathways culminating in transient or permanent
cell cycle arrest, DNA damage repair, and/or cell death (Jackson
and Bartek, 2009). A crucial target of the ATM/ATR cascade is
the tumor suppressor protein p53, a transcription factor, whose
function is lost or compromised in more than 50% of all can-
cers (Levine, 1997). Under steady-state conditions, p53 protein
is sustained at very low levels, since it is continuously being
ubiquitinylated by the Mdm2 ubiquitin ligase and thus targeted
for subsequent proteolytic degradation via the 26S proteasome.
Yet, phosphorylation of p53 by kinases of the ATM/ATR pathway
induces the dissociation of p53 from MDM2, and the subse-
quent reduction in p53 ubiquitinylation leads to a deceleration
of proteasome-mediated degradation and hence a stabilization
of p53 (Meek, 2009). Depending on the cell cycle phase and
the type as well as the extent of DNA damage, p53 can func-
tion as a modulator of the DNA damage repair process, or as
a transcriptional activator of genes, which are involved in tran-
sient or permanent cell cycle arrest, and/or cell death, respectively
(Sengupta and Harris, 2005).
APOPTOSIS
Apoptosis is one type of programed cell death. It is commonly
considered to be the prevalent form of cell death underlying daily
tissue regeneration and renewal. Morphologically, it is charac-
terized by cellular shrinkage, chromatin condensation, nuclear
fragmentation, and membrane blebbing (Figure 1). In response
to radiotherapy, apoptosis is predominantly observed in cells of
the hematopoietic system, and it is critically regulated by the
mitochondrial, intrinsic death pathway (Rudner et al., 2001; Eriks-
son and Stigbrand, 2010). The pivotal events in this context
involve the permeabilization of the mitochondrial outer mem-
brane (MOMP) and the release of various proteins, including
cytochrome c, from the mitochondrial intermembrane space
into the cytosol, thus stimulating the formation of the apop-
tosome and the activation of procaspase-9. Activated caspase-9,
in turn, triggers the activation of downstream effector caspases,
which execute the ﬁnal stages of apoptosis and the disinte-
gration of the cell (Taylor et al., 2008). Crucial regulators of
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FIGURE 1 | Different cell death modalities induced by ionizing radiation.
mitochondrial permeabilization and cytochrome c release are pro-
teins of the B cell lymphoma-2 (Bcl-2) family, including the
pro-apoptotic BH3-only (e.g., Puma) and the anti-apoptotic (e.g.,
Bcl-2) family members, which control MOMP via their impact
on the oligomerization of the effector members Bax and Bak
(Youle and Strasser, 2008). p53 links this signaling pathway to
radiation-induced DNA damage by transactivating the expres-
sion of pro-apoptotic Bcl-2 family members, such as Puma and
Noxa (Sengupta and Harris, 2005). Apart from the intrinsic
pathway, apoptosis can be induced extrinsically via the ligation
of death receptors, such as CD95 or the TRAIL receptors 1
and 2, by their corresponding ligands (Debatin and Krammer,
2004). Receptor clustering leads to recruitment and activation
of the pro-caspases-8 and -10, triggering of the caspase cas-
cade, and thus to apoptosis. Various proteins of the death
receptor pathway are known to be upregulated in response to
ionizing radiation (p53-dependently as well as -independently)
and thus might contribute to apoptosis induction (Belka et al.,
1998; Haupt et al., 2003). However, the intrinsic death pathway
appears to be the major signaling mechanism of irradiation-
induced apoptosis (Rudner et al., 2001). Notably, although p53
essentially controls the expression of various key regulators of
apoptosis, irradiation-induced apoptosis can be observed in
cancer cells with defective p53 function. Here, mechanisms,
such as p63-/p73-dependent induction of pro-apoptotic Bcl-2
members and p53-independent stimulation of death receptor
signaling have been described to be involved (Afshar et al., 2006;
Wakatsuki et al., 2008).
NECROPTOSIS AND NECROSIS
In tumor cells of epithelial origin, which reveal limited apop-
tosis induction in response to radiotherapy, radiation-induced
DNA damage – especially when combined with hyperthermia -
has been reported to stimulate necroptosis (Mantel et al., 2010;
Schildkopf et al., 2010; Figure 1). The crucial events in this context
include the hyperactivation of the DNA repair enzyme poly-ADP-
ribose-polymerase (PARP) and the subsequent and substantial
depletion of intracellular ATP levels (Vandenabeele et al., 2010;
Vanlangenakker et al., 2012). This – in a so far poorly understood
way – couples to the activation of receptor interacting protein
(RIP), the formation of the high-molecular weight necrosome,
and ﬁnally the execution of necroptosis as characterized by the
production of reactive oxygen species (ROS), lipid peroxidation,
swelling of organelles, rupture of the plasma membrane, and
release of intracellular contents (Vandenabeele et al., 2010). Apart
from necroptosis, ionizing radiation – particularly when applied
in high single doses during ablative radiotherapy – can trigger
necrosis, an accidental, uncontrolled form of cell death as a con-
sequence of excessive physico-chemical stress (Vandenabeele et al.,
2010). Moreover, secondary necrosis can occurwhen apoptotically
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dying cells are not properly and timely engulfed by neighboring
cells or professional phagocytes, respectively (Munoz et al., 2010a;
Silva, 2010). This is of speciﬁc relevance when the local phagocytic
compartment is overwhelmed due to massive apoptosis induction
in the context of tumor radiotherapy. In both cases the integrity
of the plasma membrane is lost and cellular contents, often in an
oxidatively modiﬁed and partially degraded form, leak into the
surrounding tissue.
MITOTIC CATASTROPHE
Mitotic catastrophe is a formof cell stress, which occurs in the con-
text or as a result of aberrant mitosis owing to uncoordinated or
improper entry into mitosis. It has been assigned to be the major
deathmechanism in response to irradiation-inducedDNAdamage
of cells with defects in cell cycle checkpoints and impaired DNA
repair mechanisms (e.g., cells with defective p53). In the course of
mitotic catastrophe the formation of giant cells can be observed
with aberrant nuclear morphology, centrosome hyperampliﬁca-
tion, and multiple nuclei, and/or several micronuclei (Figure 1).
These cells may survive for days, transit into senescence, or die by
delayed apoptosis or delayed necro(pto)sis, respectively (Eriksson
and Stigbrand, 2010).
SENESCENCE
Radiation-induced senescence is a condition of permanent cell
cycle arrest, which can be observed in cells, where DNA damage
is excessive and cell cycle checkpoints are still intact (Figure 1).
The hallmarks of cellular senescence include an enlarged and ﬂat-
tened cellular morphology, increased granularity, upregulation of
cyclin-dependent kinase inhibitors, such as p16INK4a, p21Waf1,
and p27Kip1, and positive staining for the senescence-associated
β-galactosidase (SA-β-Gal). The key players in this scenario are
p53 and pRB, yet senescent phenotypes have also been reported
in the absence of functional p53 (Nardella et al., 2011). Senescent
cells exit the cell cycle and do not further undergo cell division,
but may remain metabolically active. Interestingly, they have been
shown to release factors, which can be tumor suppressing as well
as tumor promoting, and which can alter the immune response
(Kuilman and Peeper, 2009; Coppe et al., 2010).
DYING CELL CLEARANCE
Higher organisms have developed impressively efﬁcient mech-
anisms of dying cell clearance as can be appreciated from the
fact that dying cells are rarely to be observed in normal tissues,
although – according to careful estimations – approximately one
million cells per second undergo apoptosis in the course of every-
day tissue turnover and regeneration (Reed, 2006). These cells are
swiftly phagocytosed and degraded, and the immune system had
to acquire the capability to distinguish them from cells, which
are dying in the context of an infection. Whereas several types
of amateur phagocytes, including ﬁbroblasts, endothelial cells,
and mesothelial cells, have been described, professional phago-
cytes, such as macrophages and dendritic cells (DCs), apparently
play a crucial role in this scenario, particularly when the local
amateur phagocytic compartment is overwhelmed (Lauber et al.,
2004; Ravichandran, 2011; Wagner et al., 2011). Macrophages
and DCs serve as professional dying cell scavengers with
discrepant tasks. While tissue resident macrophages can proﬁ-
ciently engulf and degrade huge amounts of dying prey cells,
DCs act as sentinels, which are highly potent in presenting and
cross-presenting antigens, thus stimulating, skewing, or inhibiting
adaptive immune responses, respectively (Steinman, 2007; Biswas
and Mantovani, 2010).
The sophisticated process of dying cell removal involves distinct
phases: phagocyte recruitment, prey cell engulfment, and the post-
phagocytic response (Ravichandran, 2010; Figure 2).
PHAGOCYTE RECRUITMENT
Phagocyte recruitment is accomplished by the release of solu-
ble “ﬁnd-me” signals from the dying cell (Munoz et al., 2010b;
Peter et al., 2010; Figure 3). In case of apoptotic cells, these
“ﬁnd-me” signals comprise different molecular entities. As such,
nucleotides, like ATP and UTP, have been described to trig-
ger monocyte/macrophage recruitment via the purinergic P2Y2
receptor (Elliott et al., 2009). Released proteins, including a
covalently linked dimer of ribosomal protein S19 (dRPS19),
endothelial monocyte activating polypeptide II (EMAP-II), sol-
uble fractalkine (sFKN), and the ectodomain of the IL-6 receptor
(sIL-6R) also contribute to phagocyte attraction and involve
their cognate receptors CD88, CXCR3, CX3CR1, and CD130
(Nishiura et al., 1998; Hou et al., 2006; Chalaris et al., 2007;
Truman et al., 2008). Phospholipids, such as lysophosphatidyl-
choline (LPC) and sphingosine-1-phosphate (S1P), complement
the molecular spectrum of apoptotic cell-derived “ﬁnd-me” sig-
nals and have been reported to stimulate monocyte/macrophage
chemotaxis via the G-protein coupled receptor G2A or the fam-
ily of the S1P receptors (S1PR1–5), respectively (Lauber et al.,
2003; Gude et al., 2008; Peter et al., 2008). Finally, also micro-
blebs carrying ICAM-3 have been assigned a role in phagocyte
recruitment by apoptotic cells (Segundo et al., 1999; Torr et al.,
2012). Amongst the mediators being liberated during apopto-
sis, lactoferrin (LTF) plays a special role. Its de novo expression
and release by apoptotic cells have been described, but in con-
trast to the “ﬁnd-me” signals described above, LTF exerts the
function of a granulocytic anti-attraction or “keep-out” signal,
since it exerts a deterring effect on neutrophils and eosinophils
and prevents them from invading the area of apoptotic cell death
(Bournazou et al., 2009).
Of note, all these factors are released and/or secreted while
the plasma membrane is still intact – a crucial hallmark of
bona ﬁde apoptosis, which fundamentally discriminates it from
necro(pto)sis. In the course of the latter, the disintegration of
the plasma membrane liberates the intracellular contents, and
the most abundant factors within this “releasate” act as endoge-
nous danger signals or damage-associated molecular patterns
(DAMPs) that “inform” the immune system about the tissue dam-
age (Matzinger, 1998; Lotze et al., 2007). The majority of danger
signals have been reported to exert pleiotropic effects on the
immune system, with phagocyte recruitment being one of them.
As such, high mobility group box 1 protein (HMGB-1) and its
close relative hepatoma-derived growth factor (HDGF), peroxire-
doxins (Prx), members of the S100 protein family, and heat shock
proteins (HSPs) can stimulate monocyte/macrophage attraction
by engaging the Toll-like receptors 2 and 4 (TLR2/4), the receptor
www.frontiersin.org September 2012 | Volume 2 | Article 116 | 3
“fonc-02-00116” — 2012/9/8 — 18:22 — page 4 — #4
Lauber et al. Dying cell clearance and its relevance for radiotherapy
FIGURE 2 |The multi-step process of dying cell clearance.
FIGURE 3 |The secretome and releasate of cells undergoing different forms of cell death and senescence recruit immune cells and skew the immune
response toward tolerance induction or anti-tumor immunity.
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for advanced glycation end products (RAGE), and members of
the scavenger receptor (SR) family (Eue et al., 2000; Bianchi and
Manfredi, 2007; Tsan and Gao, 2009; Shichita et al., 2012). Addi-
tionally, ATP and uric acid, which readily forms monosodium
urate (MSU) crystals in the extracellular space, have been assigned
a phagocyte attracting danger signal function. Yet, the recep-
tor for MSU crystals, if there is any, remains to be identiﬁed
(Shi et al., 2010).
In case of post-apoptotic, secondary necrotic cells, the pro-
cess of phagocyte recruitment is only poorly understood. One
could argue that the repertoire of soluble mediators released
by secondary necrotic cells should be a sum of the factors
released by apoptotic and primary necro(pto)tic cells. How-
ever, it has to be taken into account that dRP S19, EMAP-II,
sFKN, sIL-6R, LPC, S1P, and micro-blebs are released early during
apoptosis, and according to the ubiquitous presence of degrad-
ing enzymes in the extracellular space the stability of these
compounds is presumably rather limited. Hence, it is ques-
tionable if these mediators are still present and active after the
transition into secondary necrosis. Moreover, the factors liberated
during primary and secondary necrosis should differ essentially,
since the key danger signals described in the context of primary
necrosis undergo modiﬁcations during apoptosis: ATP is con-
sumed and intracellular proteins are proteolytically processed,
which might enhance as well as abolish their danger signal func-
tion (Galluzzi et al., 2012). Yet, available data on this issue are
limited. From the present point of view, the most likely can-
didates for secondary necrotic cell-derived “ﬁnd-me” signals are
MSU crystals, since the amount of releasable uric acid – owing
to the degradation of chromatin – supposedly is even higher
than in the case of primary necrosis, and HMGB-1 associated
with secondary necrotic cell-derived nucleosomes (Urbonaviciute
et al., 2008; Shi et al., 2010). In addition, annexin A1 has very
recently been shown to translocate to the outer leaﬂet of the
plasma membrane and to be proteolytically processed into a pep-
tide, which subsequently is released and stimulates monocytes/
macrophage chemotaxis during secondary necrosis (Blume et al.,
2009, 2012).
DYING CELL ENGULFMENT
When phagocytes reach the dying cells, they identify and rec-
ognize their prey by “eat-me” signals, which are exposed on the
cell surface. For apoptotic cells, the dominant “eat-me” signal
appears to be phosphatidylserine (PS), an anionic phospholipid
that during apoptosis translocates from the inner to the outer
leaﬂet of the plasma membrane (Fadok et al., 1992; Krahling
et al., 1999). PS is recognized directly by speciﬁc PS receptors,
including brain angiogenesis inhibitor 1 (BAI-1), members of
the T cell Ig and mucin family (TIM-1, -3, and -4), and the
stabilins 1 and 2 (Kobayashi et al., 2007; Miyanishi et al., 2007;
Park et al., 2007, 2008, 2009; Nakayama et al., 2009). Addition-
ally, PS can be recognized indirectly via the mediation of soluble
bridging proteins. They link PS to different engulfment receptors
of the phagocyte, and originate from the phagocyte, the dying
cell, or the interstitial body ﬂuids, respectively. Milk fat glob-
ule EGF factor 8 (MFG-E8) and its close relative developmental
endothelial locus 1 (Del-1) are examples for phagocyte-derived
bridging proteins and ligate PS to ανβ3/5 integrins (Hanayama
et al., 2002). In addition, annexin A1 can be released by the
phagocyte for apoptotic cell opsonization, but it has also been
reported to be the prototypical apoptotic cell-derived bridging
protein, although its corresponding phagocyte receptor still has
to be identiﬁed (Arur et al., 2003; Fan et al., 2004). The serum
proteins β2-glycoprotein 1 (β2GP1), protein S, and growth arrest-
speciﬁc gene 6 (Gas6) contribute to PS bridging as well and involve
members of the LDL receptor-related protein family (LRP), or
the protein tyrosine kinases Mer, Axl, and Tyro3, respectively
(Ishimoto et al., 2000; Lu and Lemke, 2001; Scott et al., 2001;
Anderson et al., 2003; Wu et al., 2005; Rothlin et al., 2007; Maiti
et al., 2008; Xiong et al., 2008). Aside from externalized PS, sev-
eral other “eat-me” signals on the surface of apoptosing cells have
been described: sites resembling oxidized low density lipopro-
tein particles and sites binding thrombospondin-1, collectins or
complement proteins have been reported to engage SRs, ανβ3/5
integrins, collectin and complement receptors in order to trigger
dying cell engulfment. Finally, also the inactivation of “don’t-
eat-me” signals, such as CD31 or CD47 and its binding partner
SIRPα, which prevent viable cells from mistakenly being ingested,
contributes to proper dying cell recognition (Brown et al., 2002;
Gardai et al., 2005).
In case of primary and secondary necrosis the mechanisms of
dying cell recognition and engulfment are not as well understood
as in the case of apoptosis. However, it appears that complement
opsonization rather represents a hallmark of secondary necrosis
than of early apoptosis, and the same seems to apply to annexin
A1 externalization (Gaipl et al., 2001; Blume et al., 2009). More-
over, although mechanistically different from PS translocation
during apoptosis, ruptures or holes in the plasma membrane lead
to an exposure of PS by primary and secondary necrotic cells.
Consequently, PS has also been attributed a role in necrotic cell
engulfment (Brouckaert et al., 2004; Bottcher et al., 2006). Of note,
very recently the ﬁrst speciﬁc “eat-me” signal of primary necrotic
cells has been identiﬁed: exposed actin ﬁlaments, which are rec-
ognized by the C-type lectin Clec9A (Sancho et al., 2009; Ahrens
et al., 2012; Zhang et al., 2012).
Ligation of engulfment receptors triggers rearrangements in
the actin cytoskeleton and thus the internalization of the dying
cell. However, the underlying molecular mechanisms are only
poorly understood and may differ fundamentally according to
the structure of the respective receptor and its downstream sig-
naling cascades. Probably the most detailed data are available
for BAI-1, a seven transmembrane domain G-protein coupled
receptor that signals via the evolutionarily conserved ELMO1–
Dock180–Rac complex (Park et al., 2007). Undoubtedly, further
studies are required in order to dissect the signaling cascades of
each engulfment receptor. On the one hand this will help to under-
stand why the morphology of apoptotic and necrotic cell ingestion
is so different from each other, with apoptotic cells being phago-
cytosed by a“zipper”-like mechanism and necrotic cells – together
with a substantial amount of extracellular material – being taken
up by macropinocytosis (Krysko et al., 2006). On the other hand,
it will contribute to elucidate, why the phagocytosis of apoptotic
and necrotic cells is so fundamentally different in terms of the
immunological outcome.
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THE POST-PHAGOCYTIC IMMUNE RESPONSE
After engulﬁng dying cells, macrophages and DCs exert discrepant
functions regarding the subsequent immune response. Whereas
macrophages predominantly degrade the phagocytic cargo and
shape the cytokine milieu for other immune cells, DCs trafﬁc
the ingested material to MHC-II- or MHC-I-dependent path-
ways of antigen-presentation or cross-presentation, respectively.
Of note, the immunological outcome of dying cell phagocyto-
sis fundamentally differs depending on the type of death the
internalized prey has previously undergone (Figure 2). It can be
said very simplistically that the uptake of apoptotic cells blunts
pro-inﬂammatory and induces anti-inﬂammatory cytokine pro-
duction in macrophages, including IL-10, TGF-β, and PGE2 (Voll
et al., 1997; Fadok et al., 1998). DCs take up apoptotic mate-
rial and process, present, or cross-present apoptotic cell-derived
antigens to T cells, thus resulting in the induction of immune
tolerance (Albert et al., 1998; Stuart et al., 2002; McGaha et al.,
2011). The “tolerate-me” signals involved in this complex pro-
cess are currently being elucidated, and PS, which is exposed on
the apoptotic cell surface, apparently is of pivotal importance in
this regard (Huynh et al., 2002; Chen et al., 2004; Doffek et al.,
2011). However, due to holes in the plasma membrane, PS is
also exposed by primary and secondary necro(pto)tic cells, but in
this case dying cell engulfment triggers a potent pro-inﬂammatory
immune response. So, somehow the tolerogenic effect of PS must
be overridden. Exposed F-actin, which ligates Clec9A, efﬁciently
stimulates cross-priming of damaged cell-derived antigens, but
alone it is not sufﬁcient to induce an adaptive immune response
to dying cells (Ahrens et al., 2012). Evidence for the nature of
the required molecules comes from a study reporting on the lack
of pro-inﬂammatory responses against necrotic cells, which have
been separated from their secretome and/or releasate (Brouck-
aert et al., 2004). Hence, it is obviously the plethora of molecules
released during primary or secondary necro(pto)sis that tip the
scale. Different studies have shown that these liberated compo-
nents, including HMGB-1-decorated nucleosomes, HSPs, ATP,
ribonucleosome particles, and others, trigger TLR-, C-type lectin-
andnod-like receptor-signaling,which is essential to promote pro-
inﬂammatory cytokine production in macrophages and efﬁcient
cross-priming in DCs (Rovere-Querini et al., 2004; Blander, 2008;
Ghiringhelli et al., 2009; Aymeric et al., 2010; Garaude et al., 2012;
Figure 3). This is further substantiated by research in the ﬁeld of
autoimmunity as defects in the process of apoptotic cell clearance
and the subsequent accumulation of secondary necrotic debris
have been shown to represent hallmarks in the etiopathogenesis of
chronic inﬂammatory and autoimmune diseases, such as systemic
lupus erythematosus (SLE; Herrmann et al., 1998; Baumann et al.,
2002; Gaipl et al., 2005, 2007a; Munoz et al., 2010a). Moreover,
mice deﬁcient in different engulfment genes or DNase II, which
is required for the proper degradation of dying cell-derived DNA,
reveal an accumulation of dying cell debris and develop a late-
onset autoimmune phenotype, including the typical interferon
(IFN) signature, closely resembling human SLE (Botto, 1998; Le
et al., 2001; Cohen et al., 2002; Hanayama et al., 2006; Kawane
et al., 2006).
In contrast to apoptotic and necro(pto)tic cells, the clearance of
senescent cells is only poorly understood. Yet, a pioneering study
has shown that senescence induction in established liver carcino-
mas results in the recruitment of macrophages, neutrophils, and
natural killer (NK) cells, and this was sufﬁcient for the clearance
of the senescent tumor cells (Xue et al., 2007). However, which
factors of the senescence-associated secretome are involved in
this scenario (Figure 3), if senescent cells are “eaten up alive” or
ﬁrst are actively killed and then phagocytosed, and which “eat-
me” signals play a role in this context, remains elusive (Figure 4;
Kuilman and Peeper, 2009; Coppe et al., 2010). Moreover, senes-
cence induction in pre-cancerous hepatocytes was observed to
stimulate an adaptive immune response depending on the inter-
action of antigen speciﬁc CD4+ T cells and macrophages (Kang
et al., 2011). Whether this might be of use for the induction of
anti-tumor immunity in established cancers has to be further
evaluated.
It should be noted that the form of cell death or cell stress
does not only shape the subsequent immune response, it has
also profound impact on the surviving neighboring cells. In
this regard, radiotherapy-induced apoptosis has been shown
to potently promote tumor cell repopulation via mechanisms
involving the caspase-3-dependent cleavage and activation of the
calcium-independent phospholipase A2 (iPLA2) and the sub-
sequent production of prostaglandin E2 (PGE2; Huang et al.,
2011; Lauber et al., 2011). Moreover, DAMPs released from
necro(pto)tic cells and particularly HMGB-1 have been reported
to stimulate autophagy as a mechanism of programed cell survival
and thus to confer resistance to radiotherapy and chemotherapy
in different models of leukemia, pancreatic, and colon cancer
(Tang et al., 2010a,b; Liu et al., 2011a,b). As mentioned above,
also the senescence-associated secretome contains factors, which
can suppress or promote the proliferation of surviving neigh-
boring cells, respectively (Kuilman and Peeper, 2009; Coppe
et al., 2010). Presumably, these proliferation-stimulating effects
of dying cells and their releasates represent integral parts of a
conserved wound-healing program, which controls tissue regen-
eration and repair under physiological conditions. However, in
the context of cancer therapy they might be counterproductive
as therapy-induced tumor cell repopulation and/or therapy resis-
tance would strongly interfere with the therapeutic aim of tumor
eradication.
DYING CELL CLEARANCE AND THE INDUCTION OF
ANTI-TUMOR IMMUNE RESPONSES IN RESPONSE
TO RADIOTHERAPY
It is well acknowledged that the induction of tumor cell death
and the abrogation of clonogenic survival by ionizing irradiation
are key determinants of its therapeutic success. However, there is
accumulating experimental evidence that particularly in the con-
text of ablative radiotherapy, during which radiation is applied
in high single doses of 10 Gy or more, complex immune mecha-
nisms contribute to tumor regression. One of the initial reports on
this issue showed that local high dose radiation therapy of trans-
planted mouse B16 melanoma stimulates the generation of tumor
antigen-speciﬁc, IFN-γ producing T cells (Lugade et al., 2005). In
the same mouse model, ablative, but not fractionated radiother-
apy was observed to drastically enhance T cell priming in tumor
draining lymph nodes paralleled by a reduction/eradication of
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FIGURE 4 | “Eat-me” signals and inactivated “don’t-eat-me” signals together with their respective phagocyte receptors orchestrate dying cell
engulfment.
the primary tumor as well as distant metastases in a CD8+ T
cell-dependent manner (Lee et al., 2009). A mechanistic explana-
tion of how these T cells are primed was provided by a recent
study showing that the intra-tumoral production of IFN-α/β in
response to high dose radiotherapy enhances the cross-presenting
capacity of tumor inﬁltrating DCs (Burnette et al., 2011). Hence,
it appears that ablative radiotherapy triggers a temporal cascade of
IFNs, which is well-known from the ﬁeld of tumor immunoedit-
ing, where IFN-α/β produced by CD11c+ cells (presumably DCs
and macrophages) enhances the cross-priming activity of CD8α+
DCs, thus stimulating the generation of IFN-γ producing CD8+ T
cells, and ﬁnally tumor rejection (Figure 5; Diamond et al., 2011;
Fuertes et al., 2011). Notably, there is a clear difference in how IFN-
α/β and IFN-γ contribute to a reduction in tumorburden. IFN-α/β
predominantly affects macrophages, DCs, and NK cells leading to
their activation and/ormaturation, theupregulationof chemokine
expression, the enhancement of antigen-presentation and cross-
presentation by DCs and a robustly augmented induction of
adaptive immune responses (Dunn et al., 2006). Consequently, in
the context of cancer immunoediting, IFN-α/β-responsiveness is
speciﬁcally required in DCs and macrophages, whereas it appears
to be dispensable in tumor cells (Diamond et al., 2011; Fuertes
et al., 2011). Nevertheless, tumor rejection in response to radio-
therapy might also be improved – at least in part – by a direct effect
of IFN-α/βon the tumor via its reported capacity of radiosensitiza-
tion (Morak et al., 2011). In strong contrast to IFN-α/β, tumor cell
responsiveness to IFN-γ obviously is an essential prerequisite for
the development of anti-tumor immune responses. Various anti-
tumor mechanisms have been reported to be exerted by IFN-γ,
including inhibition of tumor cell proliferation, apoptosis induc-
tion, inhibition of angiogenesis, and an overall enhancement of
tumor immunogenicity as characterized by an upregulation of the
MHC-I pathway,modulation/extension of the MHC-I ligandome,
and downregulation of NKG2D ligands (Dunn et al., 2006; Reits
et al., 2006; Lugade et al., 2008). Notwithstanding these direct
effects on the tumor, IFN-γ is key for the stimulation of an
anti-tumor immune response. As such, IFN-γ is vitally involved
in TH1/TC1 cell differentiation/activation, and it exerts similar
effects as IFN-α/β in terms of innate immune cell activation
and the promotion of DC-mediated antigen cross-presentation
(Dunn et al., 2006).
Once more it should be emphasized that this IFN-controlled
cascade of innate and adaptive immune responses was only
observed in case of ablative but not conventional, fraction-
ated radiotherapy (Lee et al., 2009). A feasible explanation for
this might be that ablative and fractionated radiotherapy trigger
different modalities of tumor cell death with only high dose irra-
diation stimulating primary and/or secondary necro(pto)sis. The
corresponding liberation of danger signals, including HMGB-1
and ATP, in turn stimulates the TLR4-dependent production of
IFN-α/β and other pro-inﬂammatory cytokines, initiating the
above described IFN cascade and the DC-mediated instigation
of anti-tumor T cell responses (Apetoh et al., 2007).
A key question that arises from an immuno-radiotherapeutic
point of view at this point is: How can the process of dying
cell clearance be instrumentalized or manipulated in order to
enhance the efﬁcacy of fractionated radiotherapy? Various puta-
tive approaches can be envisioned in this regard (Figure 6). The
observations made with high dose ablative radiotherapy suggest
that the temporary induction of primary/secondary tumor cell
necro(pto)sis might be beneﬁcial. Initial studies on this issue in
fact provide evidence that the combination of radiotherapy with
hyperthermia results in the induction of an immunogenic type
of cell death as characterized by the release of danger signals,
including HMGB-1 and HSP70, which foster the maturation of
DCs in vitro (Schildkopf et al., 2009, 2010, 2011; Mantel et al.,
2010). However, it remains to be elucidated, whether this trans-
lates into the productive stimulation of anti-tumorT cell responses
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FIGURE 5 | Ablative radiotherapy stimulates a cascade of interferons, which contributes to a reduction in tumor burden and the induction of
anti-tumor immunity.
in vivo. Alternatively, radiotherapy might be combined with pho-
todynamic therapy (PDT), since PDT has been reported to induce
the expression of HSPs and the release of danger signals (Castano
et al., 2006). Alone or in combination with chemotherapy PDT
leads to the stimulation of anti-tumor T cell responses in vivo
(Castano et al., 2008; Kammerer et al., 2011). Yet, if this holds
also true for its combination with radiotherapy awaits further
clariﬁcation. For tumors, which predominantly undergo apop-
tosis in response to fractionated radiotherapy, caspase inhibition
might represent an approach to overcome the tolerogenic nature
of this form of cell death, since caspase inhibition in apoptosing
cells has been reported to directly trigger necroptosis (He et al.,
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FIGURE 6 | Putative approaches with which the process of dying cell clearance can be instrumentalized in order to induce anti-tumor immunity in
the context of fractionated radiotherapy.
2009b). However, caspase inhibition might also confer radiore-
sistance due to an overall inhibition of cell death. Therefore, the
applicability of this approach has to be very carefully evaluated.
Directly interfering with apoptotic cell clearance in order to
promote the accumulation of secondary necrotic tumor cell mate-
rial might be an alternative approach to instigate the IFN cascade
described above and a concomitant anti-tumor immune response.
In this regard, annexin A5 and a mutant form of MFG-E8, which
no longer is able to bind to the vitronectin receptor, might
be valuable tools (Hanayama et al., 2002; Bondanza et al., 2004;
Gaipl et al., 2007b; Munoz et al., 2007a,b; Frey et al., 2009). In a
mouse model of tumor vaccination, annexin A5 has been shown
to impair the uptake of irradiated apoptotic lymphoma cells by
macrophages and to speciﬁcally target them to CD8α+ DCs, thus
inducing the release of proinﬂammatory cytokines and tumor-
speciﬁc immune memory, which contributed to the regression
of growing tumors and conferred resistance against tumor re-
challenge (Bondanza et al., 2004). Redirecting dying cell clearance
towardFcγ receptor-mediatedphagocytosis also appears a promis-
ing strategy for the induction of anti-tumor immune responses.
For example, opsonization with autoantibodies has been reported
to potently trigger FcyR-dependent phagocytosis of dying cells
and subsequent pro-inﬂammatory cytokineproduction (Manfredi
et al., 1998; Sarmiento et al., 2007; Grossmayer et al., 2008). Hence,
“eat-me” signal speciﬁc antibodies, including anti-PS antibodies,
or tumor antigen speciﬁc antibodies, like anti-HSP70 antibodies,
might help to utilize pro-inﬂammatory dying cell phagocyto-
sis for the induction of anti-tumor immunity (Ran et al., 2005;
Gehrmann et al., 2008; He et al., 2009a; Stangl et al., 2011a,b).
Engineering these antibodies into bi-speciﬁc antibodies coupling
to Clec9A, is of special interest in this regard, since thereby dying
tumor cell material could be speciﬁcally targeted toward the recy-
cling endosomal compartment, thus favoring cross-presentation
in BDCA3+ DCs, the alleged human equivalent to mouse CD8α+
DCs (Schreibelt et al., 2012). Seminal data obtained with differ-
ent mouse models of viral vaccination point to the direction that
this represents a successful approach of inducing vaccine-speciﬁc
immune responses (Idoyaga et al., 2011; Iborra et al., 2012; Zelenay
et al., 2012). It should be noted that Clec9A ligation alone is not
sufﬁcient to induce DC maturation and a concomitant adaptive
immune response against dying cells (Ahrens et al., 2012). Coli-
gation of additional receptors for DAMPs instead appears to be
required. Research in the ﬁeld of autoimmunity has convincingly
shown that dying cell-derived nucleosomal material is very potent
in this regard (Frisoni et al., 2007; Urbonaviciute et al., 2008).
Hence, interfering with DNase II activity, which in phagocytes
mediates the proper degradation of engulfed prey cell DNA, could
represent a promising strategy to stimulate the described IFN cas-
cade required for the induction of productive immune responses
and well-known for its crucial role in the etiopathogenesis of
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autoimmune diseases, such as SLE (Kawane et al., 2006; Marshak-
Rothstein,2006;Deng andTsao,2010). To this end, cell-permeable,
small molecule inhibitors of DNase II would be helpful, and it
remains to be elucidated whether such compounds can techni-
cally be developed. Finally, further studies are required to improve
and expand our knowledge on the process of senescent cell clear-
ance with special focus on its applicability and potential utilization
for the enhancement of tumor immunogenicity in the context of
fractionated radiotherapy.
CONCLUSION
Undoubtedly, the inductionof tumor cell death and the abrogation
of clonogenic survival by ionizing irradiation are key to its ther-
apeutic success. However, pioneering immuno-radiotherapeutic
studies have convincingly shown that a contribution of com-
plex immune mechanisms – particularly in the context of ablative
radiotherapy – can no longer be neglected. The clearance of dying
tumor cells by phagocytic cells of the innate immune system repre-
sents a crucial initiating step in this scenario. Valuable lessons can
be learned from research in the ﬁeld of autoimmunity on how the
form of cell death skews the subsequent immune response, which
cell types and molecules are involved in this context, and how
these might be utilized for the induction of productive anti-tumor
immune responses in combination with radiotherapy. Notably,
these immune responses would not only target the local tumor
but could also reach distant, out-of-ﬁeld metastases. To this end,
combined, multi-modal treatment regimes have to be developed
with the capacity to induce immunogenic forms of tumor cell
death and concomitantly activate the immune system. The correct
timing will be an essential parameter affecting the therapeutic suc-
cess of these approaches, since the priming of adaptive immune
responses takes place in the tumor draining lymph nodes, which
due to the risk of tumor cell spread and metastasis formation
are commonly removed by surgery. Hence, it might be worth
considering – carefully and on an individualized basis – to post-
pone lymph node surgery until the initial anti-tumor immune
priming has successfully been accomplished. Not only in this
regard, the close collaboration of clinical radiation oncologist, sur-
geons, radiobiologists, molecular oncologists, and immunologists
is indispensable in order to develop and optimize the personalized
therapeutic regime with the highest beneﬁt for each individual
patient.
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